Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 9:03 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 121–144 of 1,601 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Alzheimer's Disease Diagnosis Clear all
Completed No phase listed Observational Accepts healthy volunteers

Longitudinal Evaluation of Amyloid Risk and Neurodegeneration - the LEARN Study

NCT02488720
View directory record Official record
Conditions
Cognition Disorders
Interventions
Not listed
Lead sponsor
University of Southern California
Other
Eligibility
65 Years to 85 Years
Enrollment
538 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2023
U.S. locations
40
States / cities
Birmingham, Alabama • Phoenix, Arizona • Sun City, Arizona + 32 more
Source: ClinicalTrials.gov public record
Updated Nov 18, 2023 · Synced Oct 21, 2026, 9:03 PM EDT
Not listed Not applicable Interventional

An Innovative Psychosocial Intervention for Adult-Child Caregivers of Parents With Alzheimer's Disease

NCT00409279
View directory record Official record
Conditions
Alzheimer Disease
Interventions
Information, counseling and support
Behavioral
Lead sponsor
The Jacob and Valeria Langeloth Foundation
Other
Eligibility
21 Years to 90 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Oct 21, 2026, 9:03 PM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

A Master Protocol Studying Multiple Amyloid-Targeting Therapies in Healthy Participants and Participants With Alzheimer's Disease

NCT07787169
View directory record Official record
Conditions
Alzheimer Disease, Amyloid, Plaque, Amyloid, Healthy Volunteers
Interventions
LY4405094, Placebo, Florbetapir F18, Florbetaben F 18
Drug · Other
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 85 Years
Enrollment
179 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2028
U.S. locations
13
States / cities
Anaheim, California • Irvine, California • Los Alamitos, California + 10 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2026 · Synced Oct 21, 2026, 9:03 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Influence of Beta Amyloid Imaging on Care of Patients Cognitive Complaints.

NCT02309723
View directory record Official record
Conditions
Alzheimer's Disease, Mild Cognitive Impairment
Interventions
Beta amyloid imaging
Device
Lead sponsor
Tufts Medical Center
Other
Eligibility
18 Years to 100 Years
Enrollment
315 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 10, 2017 · Synced Oct 21, 2026, 9:03 PM EDT
Completed Phase 4 Interventional Results available

Neural Correlates In Mild Alzheimer's Disease

NCT00477659
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Donepezil hydrochloride
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
50 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Nov 10, 2021 · Synced Oct 21, 2026, 9:03 PM EDT
Completed Phase 3 Interventional

Memory Impairment Study (Mild Cognitive Impairment Study)

NCT00000173
View directory record Official record
Conditions
Alzheimer Disease
Interventions
Donepezil, Vitamin E
Drug
Lead sponsor
National Institute on Aging (NIA)
NIH
Eligibility
55 Years to 90 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2004
U.S. locations
63
States / cities
Phoenix, Arizona • Tucson, Arizona • Irvine, California + 53 more
Source: ClinicalTrials.gov public record
Updated Dec 11, 2009 · Synced Oct 21, 2026, 9:03 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Memantine Plus Es-citalopram in Elderly Depressed Patients With Cognitive Impairment

NCT01876823
View directory record Official record
Conditions
Mild Cognitive Impairment, Major Depressive Disorder, Alzheimer's Disease
Interventions
es-citalopram, Memantine
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
50 Years to 90 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 24, 2014 · Synced Oct 21, 2026, 9:03 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Absolute Bioavailability of a Single, Fixed Subcutaneous Dose of Aducanumab in Healthy Participants

NCT02782975
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
aducanumab
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 55 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
2
States / cities
Evansville, Indiana • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jan 13, 2017 · Synced Oct 21, 2026, 9:03 PM EDT
Completed No phase listed Observational

Identification of Patients With a High Probability of Meeting Eligibility Criteria for an Alzheimer's Disease Clinical Trial (APHELEIA)

NCT05364307
View directory record Official record
Conditions
Alzheimer Disease, Mild Cognitive Impairment, Memory Loss, Memory Disorders, Memory Impairment
Interventions
Prescreener database
Other
Lead sponsor
Global Alzheimer's Platform Foundation
Other
Eligibility
50 Years to 90 Years
Enrollment
1,555 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
18
States / cities
San Diego, California • Santa Ana, California • Aventura, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Feb 5, 2025 · Synced Oct 21, 2026, 9:03 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

The Effect of Acetylcholine on Memory and Attention

NCT00001977
View directory record Official record
Conditions
Alzheimer's Disease, Healthy
Interventions
Not listed
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
Not listed
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2000 – 2001
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 21, 2026, 9:03 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Pilot Testing Dementia-Enhanced Training and Tool for Home Hospice Clinicians

NCT05719077
View directory record Official record
Conditions
Alzheimer's Disease and Related Dementias
Interventions
EDITH-HC
Behavioral
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
19 Years to 90 Years
Enrollment
93 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
1
States / cities
New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Oct 21, 2026, 9:03 PM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Sleep Aging and Risk for Alzheimer's 2.0

NCT03278119
View directory record Official record
Conditions
Alzheimer Disease, Sleep Apnea
Interventions
PET Scan and nocturnal polysomnography
Diagnostic Test
Lead sponsor
NYU Langone Health
Other
Eligibility
55 Years to 75 Years
Enrollment
158 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 30, 2026 · Synced Oct 21, 2026, 9:03 PM EDT
Terminated Phase 1 Interventional

Study of the Pharmacokinetics and Pharmacodynamics of POSIPHEN® in Subjects With Amnestic Mild Cognitive Impairment

NCT01072812
View directory record Official record
Conditions
Alzheimer's Disease, Amnestic Mild Cognitive Impairment
Interventions
Posiphen® tartrate capsules
Drug
Lead sponsor
Annovis Bio Inc.
Industry
Eligibility
55 Years to 80 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Apr 22, 2015 · Synced Oct 21, 2026, 9:03 PM EDT
Withdrawn Phase 1 Interventional

Lymphatic System Health in Alzheimer's Disease

NCT04205539
View directory record Official record
Conditions
Alzheimer Disease
Interventions
Dexmedetomidine
Drug
Lead sponsor
Neurological Associates of West Los Angeles
Other
Eligibility
18 Years to 90 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
2
States / cities
Los Angeles, California • Santa Monica, California
Source: ClinicalTrials.gov public record
Updated Sep 28, 2022 · Synced Oct 21, 2026, 9:03 PM EDT
Completed Phase 4 Interventional

Study of the Effects of Current Drug Treatments on Levels of Certain Brain Chemicals in Alzheimer's Disease

NCT00104442
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Rivastigmine
Drug
Lead sponsor
Novartis
Industry
Eligibility
50 Years to 85 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated Dec 21, 2007 · Synced Oct 21, 2026, 9:03 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Early Detection of Mild Cognitive Impairment in Individual Patients

NCT00243451
View directory record Official record
Conditions
Mild Cognitive Impairment, Mild Alzheimer's Disease
Interventions
PET scan & fMRI
Other
Lead sponsor
Louisiana State University Health Sciences Center Shreveport
Other
Eligibility
55 Years to 85 Years
Enrollment
34 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2011
U.S. locations
1
States / cities
Shreveport, Louisiana
Source: ClinicalTrials.gov public record
Updated Sep 7, 2011 · Synced Oct 21, 2026, 9:03 PM EDT
Completed Phase 2 Interventional Results available

Multiple IV Dose Study Of PF-04360365 In Patients With Mild To Moderate Alzheimer's Disease

NCT00722046
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
PF-04360365 0.1 mg/kg, PF-04360365 0.5 mg/kg, PF-04360365 1 mg/kg, Placebo, PF-04360365 3 mg/kg, PF-04360365 8.5 mg/kg
Biological · Drug
Lead sponsor
Pfizer
Industry
Eligibility
50 Years and older
Enrollment
198 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
15
States / cities
Peoria, Arizona • Phoenix, Arizona • Miami, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Nov 7, 2022 · Synced Oct 21, 2026, 9:03 PM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate Efficacy and Safety of BAC in Patient With Alzheimer's Disease or Vascular Dementia

NCT02886494
View directory record Official record
Conditions
Alzheimer's Disease or Vascular Dementia
Interventions
BAC treatment, Matched vehicle
Drug
Lead sponsor
Charsire Biotechnology Corp.
Industry
Eligibility
40 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
10
States / cities
Tempe, Arizona • Little Rock, Arkansas • Rogers, Arkansas + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2022 · Synced Oct 21, 2026, 9:03 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

A Light Exposure Tracker Designed to Improve Circadian Rhythms - Aim 1

NCT06356337
View directory record Official record
Conditions
Alzheimer's Disease, Mild Cognitive Impairment
Interventions
Light goggles, Daily reminder test message
Device · Behavioral
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
55 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Menands, New York
Source: ClinicalTrials.gov public record
Updated Oct 14, 2025 · Synced Oct 21, 2026, 9:03 PM EDT
Completed Phase 2 Interventional Results available

Bexarotene Amyloid Treatment for Alzheimer's Disease

NCT01782742
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Bexarotene, Placebo
Drug
Lead sponsor
The Cleveland Clinic
Other
Eligibility
50 Years to 90 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Las Vegas, Nevada
Source: ClinicalTrials.gov public record
Updated Feb 12, 2016 · Synced Oct 21, 2026, 9:03 PM EDT
Completed Phase 2 Interventional

Rasagiline 1 mg and 2 mg Added to Aricept 10 mg Daily in Patients With Mild to Moderate Alzheimer's Disease (AD)

NCT00104273
View directory record Official record
Conditions
Dementia, Alzheimer's Disease
Interventions
Rasagiline
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
45 Years to 90 Years
Enrollment
376 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
31
States / cities
Huntsville, Alabama • Tucson, Arizona • Little Rock, Arkansas + 24 more
Source: ClinicalTrials.gov public record
Updated Jul 15, 2009 · Synced Oct 21, 2026, 9:03 PM EDT
Completed No phase listed Observational

A Study to Determine the Signs and Symptoms That Impact Daily Life of Participants With Irregular Sleep-Wake Rhythm Disorder

NCT04300569
View directory record Official record
Conditions
Irregular Sleep Wake Rhythm Disorder
Interventions
Non-interventional
Other
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years to 90 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
6
States / cities
Costa Mesa, California • San Diego, California • Miami, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 27, 2020 · Synced Oct 21, 2026, 9:03 PM EDT
Completed Phase 1 Interventional

Allopregnanolone for Mild Cognitive Impairment Due to Alzheimer's Disease or Mild AD

NCT02221622
View directory record Official record
Conditions
Mild Cognitive Impairment, Alzheimer Disease
Interventions
Allopregnanolone injection (intravenous solution), Placebo injection (intravenous solution)
Drug
Lead sponsor
University of Southern California
Other
Eligibility
55 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jul 5, 2019 · Synced Oct 21, 2026, 9:03 PM EDT
Completed Phase 3 Interventional

Study of Xaliproden (SR57746A) in Patients With Mild-to-Moderate Dementia of the Alzheimer's Type

NCT00104013
View directory record Official record
Conditions
Alzheimer Disease
Interventions
xaliproden (SR57746A)
Drug
Lead sponsor
Sanofi
Industry
Eligibility
50 Years and older
Enrollment
1,455 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
32
States / cities
Mesa, Arizona • Peoria, Arizona • Tucson, Arizona + 27 more
Source: ClinicalTrials.gov public record
Updated Aug 21, 2008 · Synced Oct 21, 2026, 9:03 PM EDT